Severe acute respiratory syndrome (SARS): Development of diagnostics and antivirals

Annals of the New York Academy of Sciences

Volumn 1067, Issue 1, 2006, Pages 500-505

  Sørensen, Morten Dræby ^a   Sørensen, Brian ^a   Gonzalez Dosal, Regina ^a   Melchjorsen, Connie Jenning ^a   Weibel, Jens ^a   Wang, Jing ^b   Jun, Chen Wie ^b   Huanming, Yang ^b   Kristensen, Peter ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b BGI SHENZHEN   (China)

Author keywords

Antibodies; Antiviral agents; Phage display; SARS

Indexed keywords

ANTIVIRUS AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DISEASE COURSE; EPIDEMIC; HUMAN; HUMAN CELL; MORTALITY; NONHUMAN; ONSET AGE; PHAGE DISPLAY; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

CORONAVIRUS; SARS CORONAVIRUS;

EID: 33744500999     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1354.072     Document Type: Conference Paper

References (44)

1. World Health Organization. 2003. Severe acute respiratory syndrome (SARS): multi-country outbreak. http://www.who.int/csr/don/2003_03-16/en/.
2. Rosling, L. & M. Rosling. 2003. Pneumonia causes panic in Guangdong province. Br. Med. J. 326 : 416.
3. Drosten, C. et al. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 : 1967 1976.
4. Ruan, Y.J. et al. 2003. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 361 : 1779 1785.
5. Peiris, J.S. et al. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 : 1319 1325.
6. Rota, P.A. et al. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 : 1394 1399.
7. Marra, M.A. et al. 2003. The genome sequence of the SARS-associated coronavirus. Science 300 : 1399 1404.
8. Ksiazek, T.G. et al. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348 : 1953 1966.
9. Fouchier, R.A. et al. 2003. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423 : 240.
10. Thiel, V. et al. 2003. Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. 84 : 2305 2315.
11. Leung, C.W. et al. 2004. Severe acute respiratory syndrome among children. Pediatrics 113 : e535 e543.
12. Liang, W. et al. 2004. Severe acute respiratory syndrome, Beijing, 2003. Emerg. Infect. Dis. 10 : 25 31.
13. Donnelly, C.A. et al. 2003. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 361 : 1761 1766.
14. Tan, Y.J., S.G. Lim & W. Hong. 2005. Characterization of viral proteins encoded by the SARS-coronavirus genome. Antiviral Res. 65 : 69 78.
15. Krokhin, O. et al. 2003. Mass spectrometric characterization of proteins from the SARS virus: a preliminary report. Mol. Cell Proteomics 2 : 346 356.
16. Li, G., X. Chen & A. Xu. 2003. Profile of specific antibodies to the SARS-associated coronavirus. N. Engl. J. Med. 349 : 508 509.
17. Chen, W. et al. 2004. Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. J. Med. Microbiol. 53 : 435 438.
18. Wong, S.K. et al. 2004. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279 : 3197 3201.
19. Sui, J. et al. 2004. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci. USA 101 : 2536 2541.
20. Yi, C.E. et al. 2005. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. J. Virol. 79 : 11638 11646.
21. Anand, K. et al. 2003. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300 : 1763 1767.
22. Zhai, Y. et al. 2005. Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer. Nat. Struct. Mol. Biol. 12 : 980 986.
23. Yang, H. et al. 2003. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. USA 100 : 13190 13195.
24. Chen, L. et al. 2005. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J. Virol. 79 : 7095 7103.
25. Wen, K. et al. 2004. Preparation and characterization of monoclonal antibodies against S1 domain at N-terminal residues 249 to 667 of SARS-associated coronavirus S1 protein. Di Yi Jun Yi Da Xue Xue Bao. 24 : 1 6.
26. Lin, Y. et al. 2003. Identification of an epitope of SARS-coronavirus nucleocapsid protein. Cell Res. 13 : 141 145.
27. Liu, H. et al. 2004. Recombinant scFv antibodies against E protein and N protein of severe acute respiratory syndrome virus. Acta. Biochim. Biophys. Sin. (Shanghai). 36 : 541 547.
28. Zhong, X. et al. 2005. B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein. J. Virol. 79 : 3401 3408.
29. van den Brink, E.N. et al. 2005. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J. Virol. 79 : 1635 1644.
30. Duan, J. et al. 2005. A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem. Biophys. Res. Commun. 333 : 186 193.
31. Smith, G.P. 1985. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228 : 1315 1317.
32. McCafferty, J. et al. 1990. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348 : 552 554.
33. Barbas, C.F. III. et al. 1991. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc. Natl. Acad. Sci. USA 88 : 7978 7982.
34. Hoogenboom, H.R. et al. 1991. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 19 : 4133 4137.
35. Kang, A.S. et al. 1991. Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Proc. Natl. Acad. Sci. USA 88 : 4363 4366.
36. Marks, J.D. et al. 1991. By-passing immunization: human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222 : 581 597.
37. Clackson, T. et al. 1991. Making antibody fragments using phage display libraries. Nature 352: 624 628.
38. Hust, M. & S. Dubel. 2004. Mating antibody phage display with proteomics. Trends Biotechnol. 22: 8 14.
39. Kramer, R.A. et al. 2005. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur. J. Immunol. 35: 2131 2145.
40. Kausmally, L. et al. 2004. Neutralizing human antibodies to varicella-zoster virus (VZV) derived from a VZV patient recombinant antibody library. J. Gen. Virol. 85: 3493 3500.
41. Kim, S.J. et al. 2004. Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display. Virology 318: 598 607.
42. Schofield, D.J. et al. 2003. Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine. Vaccine 22: 257 267.
43. de Carvalho Nicacio, C. et al. 2002. Neutralizing human Fab fragments against measles virus recovered by phage display. J. Virol. 76: 251 258.
44. Nguyen, H. et al. 2000. Efficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries. Clin. Exp. Immunol. 122: 85 93.